Key Stats for Merck Stock
- Past-Week Performance: -0.2%
- 52-Week Range: $73.3 to $125.1
- Current Price: $115.9
What Happened?
Merck (MRK) trades at $115.87, roughly 8% below its 52-week high of $125.14, as the Street discounts a 2028 Keytruda patent expiry against a pipeline the company now values at more than $70 billion in non-risk-adjusted commercial opportunity by the mid-2030s.
Merck’s Q4 2025 earnings, reported February 3, delivered $16.4 billion in total revenue, up 5%, anchored by $8.4 billion in Keytruda family sales, the immunotherapy drug that remains the world’s top-selling cancer treatment, rising 5% on demand in earlier-stage cancers and metastatic indications.
Welireg, Merck’s oral pill targeting a protein called HIF-2 alpha that fuels certain kidney tumors, posted Q4 sales of $220 million, up 37%, and two Phase 3 readouts filed with the FDA in February now put the drug on track for expanded kidney cancer approvals with PDUFA dates of June 19 and October 4, 2026.
Chief Financial Officer Caroline Litchfield stated at the TD Cowen 46th Annual Health Care Conference on March 3 that “our company really is transforming,” adding that Merck expects revenues to take “a shallow dip before quickly turning to strong growth within a few years” after Keytruda loses exclusivity.
Merck’s $9.03 adjusted EPS midpoint for 2026, excluding the one-time Cidara acquisition charge, combined with more than 20 new product launches including Winrevair, the pulmonary arterial hypertension drug with 110,000 cumulative U.S. prescriptions, and enlicitide, an oral cholesterol drug targeting a Q1 2027 launch, positions the company to replace the Keytruda revenue base well before the mid-2030s.
Wall Street’s Take on MRK Stock
Merck’s free cash flow nearly tripled from $3.76 billion in 2024 to $8.97 billion in 2025, and the TIKR model projects that figure more than doubling again to $20.76 billion in 2026 as Winrevair, Ohtuvayre, and Keytruda QLEX convert launch investments into durable cash generation.
MRK’s normalized EPS of $24.21 in 2025 is projected to reach $34.68 in 2026 and $42.12 in 2027, a trajectory justified by the $2.5 billion LOE headwind from Januvia and Bridion already absorbed in guidance, leaving new launches as the primary incremental driver from here.
Merck’s free cash flow margin expanded from 2.3% in 2023 to 13.8% in 2025 and the TIKR model projects 29.8% by 2027, versus AstraZeneca’s 2025 FCF margin of 20.03%, projected to decline to 16.8% by 2026 only recover back to 20.05% in 2027, a gap that reflects Merck’s operating leverage from its higher-margin oncology and cardiometabolic mix.
Fourteen analysts rate Merck a Buy, four an Outperform, and eleven a Hold, with a mean price target of $127.78 against a current price of $115.87, implying 10.3% upside, a notably compressed consensus that likely reflects LOE uncertainty rather than any deterioration in the underlying launch trajectory.
The spread between the $100.00 analyst low and $150.00 high reflects a binary read on the Keytruda patent estate: the low prices in a hard 2028 LOE cliff while the high assigns value to the method-of-use patent running to November 2029 and the QLEX subcutaneous formulation targeting 30% to 40% penetration before biosimilar entry.
What Does the Valuation Model Say?
The TIKR mid-case target of $181.88 implies 57% total return and a 9.9% annualized IRR through December 2030, driven by a net income margin expanding from 33.4% in 2025 to 39.7% in 2027 as the one-time $9 billion Cidara acquisition charge rolls off and new launches scale.
The model prices in a P/E re-rating CAGR of 5.7% in the mid case, a multiple expansion that the market currently refuses to grant because it is anchoring to 2028 LOE fear rather than the post-LOE earnings base now visible through 2030.
Welireg’s two FDA-accepted applications, with PDUFA dates of June 19 and October 4, 2026, represent the clearest near-term proof point that Merck’s post-Keytruda revenue base is not theoretical but already in regulatory motion.
CEO Rob Davis stated February 3 that Merck has “line of sight to over $70 billion of potential commercial opportunity by the mid-2030s,” a figure $20 billion higher than a year prior, signaling that the pipeline buildout is accelerating, not plateauing.
The single development that breaks the TIKR model’s FCF expansion assumption is a failure in the CORALreef Outcomes cardiovascular trial for enlicitide, which would remove the drug’s blockbuster potential and the P/E re-rating the model assigns to a diversified revenue base.
The June 19 PDUFA decision on Welireg plus Keytruda in adjuvant kidney cancer is the first hard confirmation of whether Merck’s post-Keytruda oncology franchise can carry commercial weight independently, and the number to watch is Welireg’s quarterly sales trajectory against its current $220 million Q4 2025 run rate.
Should You Invest in Merck & Co., Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up MRK stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Merck & Co., Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze MRK stock on TIKR for Free →
